Neko Health Launches in New York: What Changes Now

The Launch: Neko Health Arrives in Manhattan

On September 24, Neko Health opens its first American office. The location is SoHo, at 300 Lafayette Street, the heart of Manhattan's luxury shopping district.

Neko was born from the partnership between Daniel Ek, co-founder and CEO of Spotify, and Hjalmar Nilsonne, now the company's CEO. This launch is the clearest signal yet of a deliberate strategy: staking out the American longevity market before rivals do.

According to TechCrunch, over 25,000 New Yorkers are already on the waitlist. The company closed a $700 million Series C round last month, reporting 100,000 people already scanned. Current locations remain in the UK and Sweden.

What This Office Really Is

A SoHo office sounds like real estate marketing. The substance is something else entirely.

Neko is building a premium customer acquisition channel in the densest, wealthiest consumer market in the United States. The model combines three data sources: proprietary body scanning, blood tests, and fitness device data.

This integration creates the real value. A single scan remains replicable. Data orchestration generates lock-in. A competitor can copy the scanning technology. It cannot copy the historical data of an already acquired customer. The choice of SoHo communicates a price positioning: Neko targets the high end, those willing to pay for prevention and longevity. The location becomes part of the product. The neighborhood selects the customer. Whoever walks into the Lafayette Street location is already the profile the company is looking for.

The Competitive Shift

Longevity diagnostics is moving from experimental niche to contested category. Multiple tech founders and VC funds are entering the same space.

The competitive axis is shifting from scanning technology to physical network density. Midjourney, the AI lab known for image generation, is developing a body scanner to integrate into a spa experience. The San Francisco opening is planned for 2027.

The vendor with the deepest clinic network captures more durable revenues than the vendor with the most advanced technology. Defensibility comes from the recurring customer relationship, historical data, and subscription. Whoever secures the key cities first builds the moat. A secured city is an asset a rival must go around, not through. The market has moved.

Who Is Affected

This launch has direct implications for Function Health, Fountain Life, and VC-backed new entrants. Function Health, co-founded by wellness podcaster Dr. Mark Hyman, offers blood testing and added body scans after acquiring startup Ezra.

Capital is flowing into the sector aggressively. Function drew a $450 million loan from General Catalyst's Customer Value Fund, with repayment tied to profit sharing. A structure like this ties debt to revenue growth. It pushes Function to expand quickly to service repayment. Pricing pressure will arrive soon.

Fountain Life, the longevity company of Tony Robbins and Peter Diamandis, serves the same premium customer. Consolidation looks almost inevitable. Acquisitions of scanning startups (such as Ezra) anticipate a phase of rapid aggregation: undercapitalized players become targets. Those without capital to build the network get bought for their customer base.

From Scan to Recurring Revenue

Neko's economic value lies in the subscription. A single scan generates a one-time revenue. The ongoing relationship generates longitudinal data and annual renewals.

This explains the race for physical presence. Every secured city becomes a pool of recurring customers. Acquisition costs are amortized over years of renewals. A clinic is not a cost. It is infrastructure that generates predictable cash flows.

The model echoes software subscriptions. The difference lies in the biological data, which increases in value over time. The more historical scans a company holds, the more accurate its predictive analysis becomes. This creates a cumulative advantage that latecomers find hard to close. The first mover builds a data moat. The latecomer starts from zero while the leader analyzes years of historical series.

The Strategic Question for the Board

The board question concerns positioning over the next three years. The Chief Strategy Officer must evaluate partnership or acquisition before asset prices rise.

The CFO revisits the line item tied to corporate health benefits and employee wellness. These services will enter premium corporate packages. Demand is growing from the consumer side toward enterprise. A longevity benefit becomes a retention lever for the most sought-after talent.

The Chief Digital Officer evaluates which health-data vendor to integrate into the offering. The Technology Investor verifies a precise thesis: defensibility resides in the network and data, more than in the scanning hardware. Available capital ($700 million for Neko, $450 million for Function) confirms investor confidence in scale. The window for positioning remains narrow.

The Market Signal

The market signal: longevity diagnostics is now a race for physical distribution. The underlying technology trends toward commoditization.

Defensibility is migrating toward the recurring customer relationship and the history of their data. Neko is replicating the playbook already seen in enterprise AI. Whoever wins the deployment layer, physical presence close to the customer, wins the recurring contract.

The 100,000 scans already completed represent concrete proof of viability. Demand exists and pays. The first-mover advantage in every city translates into longitudinal data that is hard to replicate. The market rewards expansion speed. Those who slow down cede ground they will not recover.

Decisions for the Next 90 Days

The useful moves in the next quarter are concrete and urgent. The Chief Strategy Officer maps acquisition targets that are still undercapitalized. The CFO estimates the impact on corporate wellness budgets over the next two years.

• Map health-scanning vendors by geographic coverage and data base.
• Evaluate distribution partnerships before the consolidation phase.
• Review spending on premium health benefits for employees.
• Test the thesis: defensibility lies in recurring data.

Neko's American launch accelerates the competitive timeline for the entire sector. Those who wait for consolidation will pay higher multiples. The time to establish your position is this quarter, before the key cities are locked up. The window rewards fast decision-makers.